Major Players - Nanobodies Industry

The global nanobodies market is anticipated to increase over the course of the forecast period as a result of rising research and development efforts by industry participants to create treatments for diseases like diabetes and cancer. Market participants work on research and development projects to create treatments for ailments including diabetes and cancer. Over the forecast period, this is anticipated to fuel the market's expansion. The market's participants' indulgence in obtaining regulatory authorities' licenses is anticipated to fuel the worldwide nanobodies market's expansion throughout the course of the forecast timeframe. Over the course of the forecast period, rising regulatory authority approvals are anticipated to fuel the expansion of the worldwide nanobodies market. For instance, in March 2021, Taisho Pharmaceutical Co., Ltd., a manufacturer of analgesics, submitted an application for approval to manufacture and market the anti-TNF NANOBODY therapeutic, which was developed by Taisho Pharmaceutical Co., Ltd. in Japan and licensed from Ablynx, a Sanofi S.A. subsidiary, in 2015 for the treatment of rheumatoid arthritis (RA). Over the forecast period, rising cancer incidence rates are anticipated to fuel market expansion for nanobodies.

As per Coherent Market Insights, over the projected period (2021-2028), the Nanobodies Market is anticipated to grow at a CAGR of 24.1%, reaching an estimated value of US$ 237.1 Mn in 2021. 

Key Companies in the Nanobodies Industry:

Merck KGaA

The company was started in 1668 and is based in Darmstadt, Germany. Merck makes pharmaceuticals, vaccines, biologic treatments, and items for animal health. In September 2022, the business stated it would merge with Merck Animal Health after paying an unknown price for the cattle management firm Vence. In February 2021, Merck Animal Health acquired PrognostiX Poultry.

Thermo Fisher Scientific

The business was started in 1956 and is based in Waltham, Massachusetts, United States. The company offers software services, consumables and reagents, and scientific equipment. In January 2021, Thermo Fisher Scientific announced that it had paid Groupe Novasep SAS €725 million in cash to acquire Henogen SA, a Belgian manufacturer of viral vectors. In October 2022, an agreement was signed between the business and the British diagnostics firm The Binding Site Group.

PerkinElmer Inc.,

The firm was founded in 1937 and is based in Waltham, Massachusetts, United States. The business offers services, technologies, knowledge, and solutions in the field of health science. PerkinElmer declared in March 2021 that it had finished buying Oxford Immunotec Global PLC (Oxford Immunotec). PerkinElmer announced its intention to purchase Horizon Discovery Group in November 2020 for about US$383 million.

Sanofi (Ablynx)

The business was founded in 1973 and is based in Paris, France. In addition to doing research, creating pharmacological products, producing them, and distributing them, mostly to the prescription market, Sanofi also creates over-the-counter medications. On November 18, 2021, it was announced that Sanofi would give $180 million to the French company Owkin.

Novartis AG

Novartis AG was established in March 1996 and has offices in Basel, Switzerland, and Cambridge, Massachusetts. Novartis covers all types of medications, including those that are prescribed, over-the-counter, and for over-the-counter usage, for immunizations, diagnostics, eyeglasses, and veterinary care. For example, Novartis directly performs handling, marketing, operations, and research through its businesses.

Genscript

The company was started in 2002 and is based in New Jersey, U.S. Genscript Corporation offers assistance with biological research and medicine development. The business provides services for producing cell lines, protein, peptide, and antibody drugs as well as bioreagents and bio-reagents. GenScript introduced their closed-end double-stranded DNA service for CRISPR in npv 2021.

Sensei Biotherapeutics, Inc.

The firm was founded in 1999 and is based in Rockville, Maryland, United States. A business called Sensei Biotherapeutics specializes in immuno-oncology and is committed to comprehending the tumor microenvironment and strategically dealing with it in order to sway the immune system against malignancy.

*Definition:

Single domain antibodies known as nanobodies are derived from heavy-chain antibodies in mammals and have special characteristics such as nanoscale size, strong structure, steady and soluble behaviors in aqueous solution, reversible protein folding, high specificity and affinity for only one cognate target, among others.